| Title |
CD23: An overlooked regulator of allergic disease
|
|---|---|
| Published in |
Current Allergy and Asthma Reports, August 2007
|
| DOI | 10.1007/s11882-007-0050-y |
| Pubmed ID | |
| Authors |
Daniel H. Conrad, Jill W. Ford, Jamie L. Sturgill, David R. Gibb |
| Abstract |
Given the importance of immunoglobulin (Ig) E in mediating type I hypersensitivity, inhibiting IgE production would be a general way of controlling allergic disease. The low-affinity IgE receptor (FceRII or CD23) has long been proposed to be a natural regulator of IgE synthesis. In vivo research supporting this concept includes the observation that mice lacking CD23 have increased IgE production whereas mice overexpressing CD23 show strongly suppressed IgE responses. In addition, the finding that mice injected with monoclonal antibody directed against the coiled-coil stalk of CD23 have enhanced soluble CD23 release and increased IgE production demonstrates that full-length, trimeric CD23 is responsible for initiating an IgE inhibitory signal. The recent identification of ADAM10 (a disintegrin and metalloprotease) as the CD23 metalloprotease provides an alternative approach for designing therapies to combat allergic disease. Current data suggest that stabilizing cell-surface CD23 would be a natural means to decrease IgE synthesis and thus control type I hypersensitivity. |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Singapore | 1 | 3% |
| Unknown | 38 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 31% |
| Student > Bachelor | 7 | 18% |
| Researcher | 4 | 10% |
| Student > Postgraduate | 4 | 10% |
| Professor > Associate Professor | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 4 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 14 | 36% |
| Immunology and Microbiology | 7 | 18% |
| Medicine and Dentistry | 6 | 15% |
| Biochemistry, Genetics and Molecular Biology | 4 | 10% |
| Social Sciences | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 4 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2021.
All research outputs
#7,428,992
of 22,711,242 outputs
Outputs from Current Allergy and Asthma Reports
#339
of 803 outputs
Outputs of similar age
#24,694
of 68,686 outputs
Outputs of similar age from Current Allergy and Asthma Reports
#2
of 4 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 803 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,686 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.